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Abstract 11 
We report key epidemiological parameter estimates for COVID-19 identified in peer-12 
reviewed publications, pre-print articles, and online reports.  13 
Range estimates for incubation period were 1.8 to 6.9 days, serial interval 4.0 to 7.5 days, 14 
and doubling time 2.3 to 7.4 days. The effective reproductive number varied widely, with 15 
reductions attributable to interventions. Case burden and infection fatality ratios increased with 16 
age. Implementation of combined interventions could significantly reduce cases and delay 17 
epidemic peak up to one month. 18 
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These parameters for transmission, disease severity and intervention effectiveness are 19 
critical for guiding policy decisions. Estimates will likely change as new information becomes 20 
available. 21 
Introduction 22 
On December 31, 2019, Chinese authorities notified the World Health Organization 23 
(WHO) of a pneumonia cluster of unknown etiology in Wuhan. (1); A novel coronavirus was 24 
subsequently isolated. As of March 7, 2020, the disease and causative agent, officially named 25 
COVID-19 and SARS-CoV-2 respectively, had resulted in 101,927 cases and 3,486 deaths in 94 26 
countries spanning 6 continents.(2) The spectrum of illness ranged from asymptomatic infection, 27 
to mild disease (e.g., fever, dry cough and myalgias), pneumonia and death.  Roughly 20% of 28 
cases require hospitalization for shortness of breath; death is associated with increasing age and 29 
underlying comorbidities (e.g., hypertension, cardiovascular disease and diabetes).(3)  30 
Here, we review important parameters of COVID-19 transmission dynamics from 31 
statistical and mathematical modeling studies using epidemiologic data reported in the first 60 32 
days of the epidemic. We estimate the key components that contribute to future modeling on the 33 
effects of non-pharmaceutical interventions (NPIs) and to inform critical resource allocation 34 
decisions.(4) Data estimates are  current as of March 6, 2020, a few days before WHO 35 
characterized COVID-19 as a pandemic on March 11, 2020 (WHO Director General remarks, 36 
https://www.youtube.com/watch?v=sbT6AANFOm4&feature=youtu.be), and subject to change 37 
as more information becomes available.  38 
Methods and Results 39 
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We reviewed the literature on key epidemiological parameters (Table 1) relating to the 40 
COVID-19 epidemic. This is not a formal systematic review as the epidemic is rapidly 41 
unfolding, and useful data sources exist that have not yet been peer-reviewed. We searched the 42 
peer-reviewed and gray literature, including pre-prints, research reports, and forum posts. 43 
Searches for individual parameters were conducted from February through March 6, 2020 on 44 
PubMed, medRxiv, bioRxiv, arXiv, SSRN, Research Square, Virological, Imperial College 45 
COVID reports, and Wellcome Open Research. Search terms centered on the various names of 46 
the disease and virus over the course of the epidemic (“nCoV”, “COVID”, “SARS-CoV-2”, 47 
“novel coronavirus”), and keywords relating to each of the epidemiologic parameters or 48 
characteristics considered (see Supplementary Table 1). Genetic epidemiology estimates, such as 49 
evolutionary rate and time from last common ancestor were selected from Virological 50 
(http://virological.org/). Articles in English and Chinese were included if they used mathematical 51 
or statistical methods for adjustment of different biases and if they were either: i)  Peer-reviewed 52 
or ii)  non-peer reviewed requiring established methods (i.e., clarity about the data used, known 53 
statistical methods, and reported uncertainty).(5–8)  54 
 55 
For each parameter, characteristics such as study population, assumptions, and analytical 56 
methods were summarized when patterns were discernible across estimates. Estimates were 57 
summarized as ranges to reflect remaining uncertainty. No meta-analyses were performed.  58 
 59 
R0 and R 60 
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One of the key early indicators of transmissibility of a novel pathogen is R0, the basic 61 
reproduction number, which represents the average number of people infected by an incident 62 
individual in a fully susceptible population. Values for R0 above one are considered a critical 63 
threshold for epidemic growth. Mean R0 estimates for Hubei Province, China ranged widely, 2.1-64 
5.1 (peer-reviewed) and 2.0-7.7 (Majumder and Mandl, unpub. data, 65 
https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3524675; Liu et al., unpub. data, 66 
https://www.biorxiv.org/content/10.1101/2020.01.25.919787v2; Mizumoto et al., unpub. data, 67 
https://www.medrxiv.org/content/10.1101/2020.02.12.20022434v2.full.pdf; Zhou, unpub. data, 68 
https://www.medrxiv.org/content/10.1101/2020.02.15.20023440v2.full.pdf; Sun et al., unpub. 69 
data, https://www.medrxiv.org/content/10.1101/2020.02.17.20024257v1), reflecting a variety of 70 
assumptions and methods utilized and data uncertainty (Figure 1).(9–14) A subset of more recent 71 
estimates accounted for the broad restrictions implemented on January 23 in Hubei explicitly and 72 
were lower than earlier estimates (1.0-2.9); Sun et al., unpub. data, 73 
https://www.medrxiv.org/content/10.1101/2020.02.17.20024257v1; Xu et al., unpub. data, 74 
https://www.medrxiv.org/content/10.1101/2020.02.25.20024398v1; Wan et al., unpub. data, 75 
https://www.medrxiv.org/content/10.1101/2020.02.16.20023804v1). Mean R0 estimates for 76 
provinces outside of Hubei or for all of China were similar to those for Hubei before the 77 
implementation of travel restrictions (peer-reviewed range: 0.4-3.9; preprint range: 0.6-6.4; Liu 78 
et al., unpub. data, https://www.biorxiv.org/content/10.1101/2020.01.25.919787v2;  Sun et al., 79 
unpub. data, https://www.medrxiv.org/content/10.1101/2020.02.17.20024257v1; Xu et al., 80 
unpub. data, https://www.medrxiv.org/content/10.1101/2020.02.25.20024398v1; Tindale et al., 81 
unpub. data, https://www.medrxiv.org/content/10.1101/2020.03.03.20029983v1; Shen et al., 82 
unpub. data, https://www.biorxiv.org/content/10.1101/2020.01.23.916726v1; Wang et al., unpub. 83 
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data, https://www.medrxiv.org/content/10.1101/2020.02.29.20029421v1.full.pdf; Ku et al., 84 
unpub. data, https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3543589; Song et al., unpub. 85 
data, http://medrxiv.org/lookup/doi/10.1101/2020.02.29.20029421).(11,14–17) R0 estimates for China 86 
and cases outside China attributed to exportation (peer-reviewed range: 2.1-3.2; preprint range: 87 
2.1– 5.7; Read et al., unpub. data, 88 
https://www.medrxiv.org/content/10.1101/2020.01.23.20018549v2.full.pdf; Zhang and Wang, 89 
unpub. data, https://www.biorxiv.org/content/10.1101/2020.01.25.919688v3; Zhou et al., unpub. 90 
data, https://www.medrxiv.org/content/10.1101/2020.02.06.20020941v1.full.pdf; Volz et al., 91 
unpub. data, https://www.imperial.ac.uk/media/imperial-college/medicine/sph/ide/gida-92 
fellowships/Imperial-College---COVID-19---genetic-analysis-FINAL.pdf),(14,18,19),estimates 93 
for the Diamond Princess cruise ship (mean R0 of approximately 2.2),(20) and estimates for 94 
Singapore and Republic of Korea (range: 2.6-3.2; Tindale et al., unpub. data, 95 
https://www.medrxiv.org/content/10.1101/2020.03.03.20029983v1) were generally lower. A 96 
meta-analysis of seven early COVID-19 studies that accounted for uncertainty in assumptions 97 
estimated an R0 of 2.9 (95% CI: 2.1-4.5; Park et al., unpub. data, 98 
https://www.medrxiv.org/content/10.1101/2020.01.30.20019877v4).  99 
 100 
High variability in R0 estimates can result from a mix of data (e.gs., time period of cases 101 
analyzed; data available by onset date), methods (e.gs., R0 as a component of early exponential 102 
growth; fitting case data to compartmental models), and assumptions (e.gs., serial intervals; case 103 
ascertainment). In particular, serial interval estimates directly affect R0: shorter serial intervals 104 
suggest that fewer transmission events are required for rapid growth. However, most R0 105 
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estimates reviewed here employed serial intervals values between 7.5 (COVID-19) and 8.4 106 
(SARS); these differences likely had limited effects.(7,9) 107 
 108 
Importantly, R0 reflects average transmission, not individual-level transmission. 109 
Variability (dispersion) among individual-level contacts and transmission potential can lead to 110 
many individuals infecting no additional people, while others infect many as previously observed 111 
for the Severe Acute Respiratory Syndrome (SARS) and the Middle East Respiratory Syndrome 112 
(MERS).(21,22) This pattern has also been observed for COVID-19 with estimates of the 113 
dispersion parameter below one (e.g., 0.5 in Singapore (Tariq et al. unpub. data, 114 
https://www.medrxiv.org/content/10.1101/2020.02.21.20026435v4.full.pdf), 0.54 in China (14),  115 
0.58 in Shenzhen (16). This implies that a minority of cases may cause the majority of infections, 116 
e.g., in Shenzhen, 8.9% of cases were found to cause 80% of infections. (16) Rigorous contact 117 
tracing data are needed to improve these estimates and identify opportunities to tailor 118 
interventions accordingly. (23) 119 
Explicit estimates of the time-varying or effective reproduction number, R (often referred 120 
to as Rt or RE), can identify changes in transmission over time as a result of interventions and 121 
acquired immunity. Mean estimates of R before January 23 generally fall within the 2.3 to 2.6 122 
range (peer-reviewed) and 3.9 to 6.2 range (preprints; Liu et al., unpub, data, 123 
https://www.biorxiv.org/content/10.1101/2020.01.25.919787v2; Wang et al., unpub. data,  124 
https://www.medrxiv.org/content/10.1101/2020.03.03.20030593v1).(24,25) Shortly after the 125 
travel restrictions, R estimates ranging from 0.4-1.0 (peer-reviewed) to 0.2-3.4 (preprints) 126 
indicated a decrease in transmission in Wuhan and other parts of China (Liu et al., unpub data, 127 
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https://www.biorxiv.org/content/10.1101/2020.01.25.919787v2; Mizumoto et al., unpub. data, 128 
https://www.medrxiv.org/content/10.1101/2020.02.12.20022434v1.full.pdf; You et al., unpub. 129 
data, https://www.medrxiv.org/content/10.1101/2020.02.08.20021253v2.full.pdf; Wan et al., 130 
unpub. data, https://www.medrxiv.org/content/10.1101/2020.02.16.20023804v1; Ku et al., 131 
unpub. data, https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3543589; Wang et al., unpub. 132 
data, https://www.medrxiv.org/content/10.1101/2020.03.03.20030593v1.full.pdf; Chong et al., 133 
unpub. data, https://www.medrxiv.org/content/10.1101/2020.03.02.20028704v1.full.pdf; Chen et 134 
al.,unpub data, https://arxiv.org/pdf/2003.00305v1.pdf).(16,24) In Singapore and the Republic of 135 
Korea, declines in R estimates also suggest decreases in transmission; 1.1 to 0.7 as of February 136 
14 in Singapore, and 1.5 (95% CI: 1.4, 1.6) in Republic of Korea up to February 27 (Tariq et al., 137 
unpub. data, https://www.medrxiv.org/content/10.1101/2020.02.21.20026435v6.full.pdf).(26) 138 
The R estimate for the Diamond Princess cruise ship suggests high transmission before and 139 
immediately after movement restrictions on the ship (median R of 12.1 [95% CrI: 8.2, 17.2]  on 140 
February 7, two days post-quarantine), with rapid decrease thereafter (median R of 0.35 [95% 141 
CrI: 0.02, 2.19] as of February 18).(27) Together, these estimates suggest R0 is high, yet 142 
intensive interventions can reduce transmissibility (R) substantially. 143 
 144 
Incubation period 145 
The incubation period is the time between infection and symptom onset. Seven studies 146 
(10 estimates) were included in this review; range 1.8 to 9.0 days (Figure 2, Supplemental Tables 147 
2 & 3; Tindale et al., unpub. data, 148 
https://www.medrxiv.org/content/10.1101/2020.03.03.20029983v1; Lu et al., unpub. data, 149 
Reserved space. Do not place any text in this section. Include the mandatory author checklist or 
your manuscript will be returned. Use continuous line numbering in your manuscript.  
 
https://www.medrxiv.org/content/10.1101/2020.02.19.20025031v1).(9,28–31) Among the 150 
articles in peer-reviewed literature, the mean incubation period was 1.8 to 6.9 days.(9,28–31) 151 
 152 
Serial interval 153 
The serial interval is the average time between symptom onset of a primary and 154 
transmission associated secondary case. Seven studies (10 estimates) estimated the mean serial 155 
interval between 4.0 and 7.5 days (Figure 3, Supplemental Tables 2 & 3; Tindale et al., unpub. 156 
data, https://www.medrxiv.org/content/10.1101/2020.03.03.20029983v1; Zhao et al., unpub. 157 
data, https://www.medrxiv.org/content/10.1101/2020.02.21.20026559v1).(9,31–34) Ganyni et al. 158 
estimated the mean generation interval of 5.21 in Singapore and 3.95 in Tianjin China.(34) 159 
 160 
Doubling time 161 
The doubling time is the average time period it takes for the daily case count to double. 162 
Utilizing both genetic and case data over several locations and time periods, 11 studies estimated 163 
a mean doubling time of 2.3 to 7.4 days (Figure 4, Supplemental Tables 2 & 3; Rambaut, unpub. 164 
data, http://virological.org/t/phylodynamic-analysis-176-genomes-6-mar-2020/356; Bedford, 165 
unpub. data, http://virological.org/t/phylodynamic-estimation-of-incidence-and-prevalence-of-166 
novel-coronavirus-ncov-infections-through-time/391; Pinotti et al., unpub. data, 167 
https://www.medrxiv.org/content/10.1101/2020.02.24.20027326v1; Zhao et al., unpub. data, 168 
https://www.medrxiv.org/content/10.1101/2020.02.06.20020941v1; Volz et al., unpub. data, 169 
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https://www.imperial.ac.uk/media/imperial-college/medicine/sph/ide/gida-fellowships/Imperial-170 
College---COVID-19---genetic-analysis-FINAL.pdf ).(9,11,15,18,19,35)  171 
 172 
Infectious period 173 
The infectious period is the period of time in which an infected host, with or without 174 
symptoms, can transmit to susceptible individuals.  One estimate (You et al., unpub. data, 175 
https://www.medrxiv.org/content/10.1101/2020.02.08.20021253v2). Based on data from 67 176 
cases, estimated a mean infectious period of 10.91 days (standard deviation,  3.95 days). Little is 177 
known about how characteristics of an infected person, such as age, severity and clinical 178 
progression, affect overall infectious period estimates.  179 
 180 
Severity 181 
Clinical progression 182 
We did not identify mathematical or statistical models that examine clinical disease 183 
progression. We include empiric findings detailed in the WHO China mission report, which has 184 
been used to inform other models.(36) 185 
 186 
Within China 187 
The majority of >75,000 cases of COVID-19 reported through March 6 have been from 188 
Hubei province. Among 55,924 confirmed cases in China as of February 20, the median age was 189 
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51 years (range 2 days-100 years) with most between 30–69 years (77.8%).  The clinical 190 
distribution was: 80.4% mild/moderate, 13.8% severe and 6.1% critically ill (Supplemental 191 
Table 4). Only 2.4% of reported cases were among persons < 19 years old.(36) Severe disease 192 
was reported among those with increased age (over 60) and comorbidities such as hypertension, 193 
diabetes, cardiovascular disease, chronic respiratory disease, and cancer.(37) Fatality estimates 194 
have come primarily from elderly Wuhan residents,(38)  suggesting substantially higher lethality 195 
compared with outside Hubei (Figure 5).  196 
 Outside China 197 
The age-distribution of cases and deaths detected outside China has been wider than that 198 
within China.(38) This difference may result from higher sensitivity surveillance for travelers 199 
compared to cases within China, particularly in countries on high alert, such as Thailand and 200 
Japan, which implemented temperature screening at airports. In general, early severe cases are 201 
more likely to be detected than mild cases resulting in higher severity estimates early on. Cases 202 
among travelers might also generally be younger due to age-specific differences in travel.  203 
A broader spectrum of clinical severity has been observed in travel-associated and locally 204 
acquired cases reported outside of China, likely reflecting more robust surveillance for SARS-205 
CoV-2. Severity ranges from asymptomatic infection, to symptoms such as fever and fatigue, as 206 
well as mild to severe respiratory symptoms including cough and pneumonia. Cases have been 207 
reported in persons with previously good health and no known comorbidities.(39) Differences in 208 
severity have also been observed within transmission chains.(40–43) 209 
 210 
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Case and Infection Fatality Ratio 211 
The case fatality ratio (CFR) is the proportion of cases which result in death. There are 212 
several variations of CFR, including symptomatic (sCFR), laboratory-confirmed (cCFR), 213 
hospitalization (HFR), and infection (IFR). Eleven studies, estimating either CFR or a variation 214 
of CFR, were included in this review (Figure 5). Most estimates were based on data from China. 215 
However, a few are from outside China or from the Diamond Princess cruise ship (38,44) 216 
Estimates of CFR generally did not include specific case definitions, and ranged from 0.9% to 217 
18.9%. Moreover, CFR is highly variable across situations (i.e., general population, hospitalized 218 
or critically ill). Critically ill patients' central estimates range between 8.0% and 28.7% (Deng et 219 
al., unpub. data, https://www.medrxiv.org/content/10.1101/2020.03.04.20031005v1). Notably, 220 
IFR seems to be more consistent across studies, with central estimates around 0.6% in two peer-221 
reviewed studies from mainland China (38,44), yet higher at 3.3% in Hubei, China, 3% in 222 
Northern Italy (Hauser et al., unpub. data, 223 
https://www.medrxiv.org/content/medrxiv/early/2020/03/30/2020.03.04.20031104.full.pdf), and 224 
and lower at 0.2% to 1.6% in Asia and Europe (Figure 5 and Supplementary Table 5). 225 
 226 
There was evidence of a strong age-gradient in both CFR and IFR, with the elderly being 227 
at a higher risk.(42) IFR presents a strong age gradient, with an IFR of  0.007% in children, 228 
between 1.9% and 4.6% in those aged 60-69, and between 7.8% and 18% in those aged >80 (38). 229 
Hospitalization rates were also age dependent:<0.04% in children, 11.8% in those aged 60-69 230 
and 18.4% among those aged 80 or more (38).   231 
 232 
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Viral Evolution and Genomic Epidemiology 233 
Virus genome sequences from a representative sample of cases can be used for 234 
calculating the evolutionary rate, date of introduction to the human population, size of outbreak, 235 
and estimating the reproduction number.(45–48)  The evolutionary rate is the rate at which 236 
mutations accumulate per base pair in the genome over the course of a year. Estimates have 237 
ranged from 0.8x10-3 to 1.2x10-3 (Table 2; Sciré et al., unpub. data, 238 
http://virological.org/t/update-2-evolutionary-epidemiological-analysis-of-128-genomes/423; 239 
Duchene et al., unpub. data, http://virological.org/t/temporal-signal-and-the-evolutionary-rate-of-240 
2019-n-cov-using-47-genomes-collected-by-feb-01-2020/379; Hill and Rambaut, unpub. data, 241 
http://virological.org/t/phylodynamic-analysis-of-sars-cov-2-update-2020-03-06/420; Rambaut, 242 
unpub. data, http://virological.org/t/phylodynamic-analysis-176-genomes-6-mar-2020/356; 243 
Bedford, unpub. data, http://virological.org/t/phylodynamic-estimation-of-incidence-and-244 
prevalence-of-novel-coronavirus-ncov-infections-through-time/391). These evolutionary rates 245 
are similar to that of MERS-CoV and SARS-CoV-1. The data suggests that the COVID-19 246 
outbreak was started by a single spillover event occurring in late 2019 (Table 2), and supported 247 
by first case reported data in December 2019 (Sciré et al., unpub. data, 248 
http://virological.org/t/update-2-evolutionary-epidemiological-analysis-of-128-genomes/423; 249 
Duchene et al., unpub. data, http://virological.org/t/temporal-signal-and-the-evolutionary-rate-of-250 
2019-n-cov-using-47-genomes-collected-by-feb-01-2020/379; Hill and Rambaut, unpub. data, 251 
http://virological.org/t/phylodynamic-analysis-of-sars-cov-2-update-2020-03-06/420; Rambaut, 252 
unpub. data, http://virological.org/t/phylodynamic-analysis-176-genomes-6-mar-2020/356; 253 
Bedford, unpub. data, http://virological.org/t/phylodynamic-estimation-of-incidence-and-254 
prevalence-of-novel-coronavirus-ncov-infections-through-time/391; Volz et al., unpub. data, 255 
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https://www.imperial.ac.uk/media/imperial-college/medicine/sph/ide/gida-fellowships/Imperial-256 
College---COVID-19---genetic-analysis-FINAL.pdf).(49) Analysis of viral genomes can also be 257 
used to estimate doubling time and reproduction number.  258 
 259 
Effectiveness of Non-Pharmaceutical Interventions (NPIs) 260 
NPIs include interventions at individual and community levels. At the individual level, NPIs 261 
examined in modeling studies included voluntary home isolation or quarantine (Supplementary 262 
Table 6). At the community level, NPIs included school and workplace closures and canceling or 263 
postponing large public gatherings (see Supplementary Table 7 for definitions). Modeling can be 264 
used to estimate the effectiveness of components of these interventions (e.g. case detection), the 265 
interventions themselves (e.g. case isolation) or combinations of interventions (e.g. case and 266 
contact isolation). In total, 29 articles were identified; of these, 17 met the inclusion criteria for 267 
this review (Table 3; Pinotti et al., unpub. data, 268 
https://www.medrxiv.org/content/10.1101/2020.02.24.20027326v1; Niehus et al., unpub. data, 269 
https://www.medrxiv.org/content/10.1101/2020.02.13.20022707v2; Gostic et al., unpub. data, 270 
https://www.medrxiv.org/content/10.1101/2020.01.28.20019224v2; Adiga et al., unpub. data, 271 
https://www.medrxiv.org/content/10.1101/2020.02.20.20025882v2; Lai et al., upub. data, 272 
https://www.medrxiv.org/content/10.1101/2020.03.03.20029843v3.full.pdf; Zhang et al., unpub. 273 
data, https://www.medrxiv.org/content/10.1101/2020.03.04.20031187v1; Clifford et al., unpub. 274 
data, https://cmmid.github.io/topics/covid19/screening-outbreak-delay.html; Bhatia et al., unpub. 275 
data https://www.imperial.ac.uk/media/imperial-college/medicine/sph/ide/gida-276 
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fellowships/Imperial-College-COVID19-international-surveillance-21-02-277 
2020.pdf).(11,15,18,50–55) 278 
 279 
Case screening and detection 280 
Recent articles have addressed the efficacy of screening and detection by surveillance 281 
systems in different countries (Pinotti et al., unpub. data, 282 
https://www.medrxiv.org/content/10.1101/2020.02.24.20027326v1; Niehus et al., unpub. data, 283 
https://www.medrxiv.org/content/10.1101/2020.02.13.20022707v2; Bhatia et al., unpub. data 284 
https://www.imperial.ac.uk/media/imperial-college/medicine/sph/ide/gida-fellowships/Imperial-285 
College-COVID19-international-surveillance-21-02-2020.pdf).(50) Two studies used data from 286 
Singapore (known for having a reliable health reporting system) as benchmarks to estimate the 287 
sensitivity of surveillance systems in other countries (Niehus et al., unpub. data, 288 
https://www.medrxiv.org/content/10.1101/2020.02.13.20022707v2; Bhatia et al., unpub. data 289 
https://www.imperial.ac.uk/media/imperial-college/medicine/sph/ide/gida-fellowships/Imperial-290 
College-COVID19-international-surveillance-21-02-2020.pdf). Both articles agreed that only a 291 
fraction of cases (22%-64%) are captured by surveillance systems, varying by country. A more 292 
recent study found similar results (36% detected cases), and lower ascertainment when 293 
repatriations were considered (Pinotti et al., unpub. data, 294 
https://www.medrxiv.org/content/10.1101/2020.02.24.20027326v1). 295 
  296 
Case isolation and quarantine of contacts 297 
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One study considered different scenarios in which the reproduction number and 298 
transmission before symptom onset were varied to study the controllability of the outbreak.(50) 299 
The authors found that as R0 increased, the percentage of contacts to be traced increased. The 300 
delay between symptom onset and isolation also affected the controllability of the outbreak. For 301 
values of R0 >2.5, contact tracing and isolation were successful at stopping transmission when < 302 
1% of transmission occurred before symptom onset. For these two parameters, case isolation 303 
alone would be unlikely to control transmission within 3 months. 304 
  305 
Traveler screening 306 
Two studies considered models in which passengers are screened before departing an 307 
area with local transmission and upon arrival to destination (Gostic et al., unpub. data, 308 
https://www.medrxiv.org/content/10.1101/2020.01.28.20019224v2).(51), demonstrating  that a 309 
relatively low number of cases would likely be detected (34%-54%). Different factors affect the 310 
under-detection of cases, including country ability to detect them. Some of those factors include 311 
asymptomatic infections, infections with mild clinical symptoms, limited care-seeking behavior, 312 
case definition, and under-recognition of cases by clinicians. A third study suggests that exit and 313 
entry screening combined with traveler sensitization can delay a local outbreak by >83 days, 314 
with no > 1 infected traveler per week (Clifford et al., unpub. data, 315 
https://cmmid.github.io/topics/covid19/screening-outbreak-delay.html). 316 
 317 
Travel restrictions 318 
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On January 23, 2020, travel bans were implemented from Wuhan city. Within China, this 319 
resulted in a delay of three days, on average, of disease arrival.(52) Cities, implementing the ban 320 
before their first case was detected observed fewer cases than cities implementing the ban after 321 
their first case.(52) Another study found that 130 cities in China had >50% chance of having a 322 
COVID-19 case imported from Wuhan in the three weeks preceding the implementation of travel 323 
restrictions, suggesting that there were cases outside of Wuhan before the travel ban.(15) 324 
Analysis of the effect of the Wuhan travel ban, including the implementation of long-range travel 325 
restrictions on January 23, showed no noticeable difference for the epidemic trajectory of 326 
Wuhan, while delaying the occurrence of cases for other locations in China by three days.(18) 327 
Another study found that travel restrictions would delay the epidemic spread throughout China 328 
by two days.(53) 329 
  330 
Internationally, several countries implemented travel bans. One modeling study estimated 331 
how travel restrictions from China impacted time of arrival of the infected individuals (Adiga et 332 
al., unpub. data, https://www.medrxiv.org/content/10.1101/2020.02.20.20025882v2). It found 333 
that countries in Africa and South America would likely observe the biggest delay, 11 and 9 day, 334 
respectively. Another study found that travel reductions of up to 90% of had only a modest effect 335 
unless paired with public health interventions and behavioral changes to achieve a considerable 336 
reduction in disease transmission.(18) 337 
  338 
Cancellation of events and public gatherings 339 
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One study analyzed a range of interventions such as suspending public transport, closing 340 
entertainment venues, and banning public gatherings.(52) Varying by city and number of control 341 
measures adopted, the study found that cities that implemented a Level 1 response (at least two 342 
control measures) before the first case was confirmed had 37% fewer cases in the week after the 343 
first case identified compared with cities that started control thereafter. Locations that closed 344 
entertainment venues and banned public gatherings early in the outbreak reported fewer cases 345 
during the first week. 346 
  347 
Finally, four studies estimated the effects of transmission reduction in China when NPI 348 
mitigation strategies were combined (Lai et al., upub. data, 349 
https://www.medrxiv.org/content/10.1101/2020.03.03.20029843v3.full.pdf).(11) The combined 350 
interventions significantly reduced the number of cases observed and delayed epidemic peak by 351 
>1 month. It was found that earlier intervention of social distancing could significantly limit the 352 
epidemic in mainland China. The number of infections could have been reduced up to 98.9%, 353 
and the number of deaths reduced by 99.3% as of Feb 23, 2020 (Zhang et al., unpub. data, 354 
https://www.medrxiv.org/content/10.1101/2020.03.04.20031187v1). A different group found 355 
that following the implementation of control measures, growth rates became negative in most 356 
locations, and that drastic control measures implemented in China substantially mitigated 357 
COVID-19 spread.(55)  358 
 359 
  360 
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Community behavior modification 361 
One research group performed an online survey after the first case of COVID-19 was 362 
reported in Hong Kong. Their results showed that 39%-88% of the people surveyed had adopted 363 
social distancing measures.(54) 364 
Discussion 365 
Modeling can provide estimates of disease transmission parameters for planning and 366 
response during epidemics. Investigators around the world have been trying to understand the 367 
transmission dynamics and severity of disease, as well as the effects that different interventions 368 
have had on the course of the epidemic through advanced analytics and modeling. However, 369 
transmission parameter estimates are limited by the availability and comprehensiveness of data 370 
early in the epidemic. Some parameters can be estimated from genetic sequencing data, but these 371 
estimates are heavily influenced by biases in sampling and inaccuracies in sequencing. Although 372 
efforts to collect and share clinical, epidemiological, and sequence data have been remarkably 373 
timely, there remain outstanding gaps in knowledge. 374 
 375 
Several parameters presented in this review are context specific, such as R0 values or 376 
CFR measurements. Although the characteristics of SAR-CoV-2 are unlikely to change, 377 
responses to transmission will vary. Several factors affect the trajectory of an epidemic in 378 
different locations, such as population density, health system infrastructure, transportation 379 
robustness, cultural practices, and poverty levels.(56) Available data from China may not be 380 
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reflective of secular trends elsewhere. As other countries develop more cases, more robust data 381 
will be available for modeling and extrapolation for countries not yet affected.   382 
 383 
Challenges in assessing severity of clinical outcomes during an new emerging epidemic 384 
have been discussed in-depth elsewhere and are not covered here.(7,8) However, there remain 385 
four challenges. First, early in an outbreak, data are heavily biased towards severe cases. 386 
Estimates of the CFR in those patients with known outcomes may be biased upwards until the 387 
extent of clinically milder disease is determined. Second, there is a period between onset of 388 
symptoms and final clinical outcome (death vs survival).(57,58) During a growing epidemic, the 389 
final clinical outcome of most reported cases is typically unknown. This is particularly true with 390 
COVID-19 where severely ill patients may be hospitalized for many days. The crude CFR will 391 
underestimate the fatality risk among early epidemic cases.(7,8,58) Third, while the epidemic is 392 
growing there will be a bias towards having observed cases with recent symptom onset and 393 
outcomes. Therefore, estimates should be adjusted for the growth rate of the epidemic.(8) Fourth, 394 
over-representation of men, elderly people with co-morbidities and people with respiratory risk 395 
factors (smoking, etc.) may result from observation bias or exposure differences and affect CFR 396 
estimates.  397 
 398 
Country preparedness and clinical care capacity will affect patient outcomes. Delayed 399 
diagnosis and treatment, limited knowledge of the natural history of infection, and rapid 400 
escalation of cases can affect clinical outcomes  Thus, fatality in patients cared for very early in a 401 
country’s epidemic may be greater than for later patients.(7) More information on the proportion 402 
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of individuals requiring healthcare, level (outpatient, inpatient and intensive care)  and duration 403 
of care required are essential for predicting healthcare needs as the epidemic progresses. 404 
 405 
Pre-symptomatic or asymptomatic transmission, if substantial, might have critical 406 
implications for control efforts. Empiric evidence of such potential transmission includes: i) a 407 
serial interval and generation time that were estimated shorter than the incubation period, 408 
(Tindael et al., unpub.data, https://www.medrxiv.org/content/10.1101/2020.03.03.20029983v1; 409 
Lu et al., unpub. data, https://www.medrxiv.org/content/10.1101/2020.02.19.20025031v1); ii) 410 
similarly high viral load  in asymptomatic and symptomatic cases;(34,59) and iii) documentation 411 
of cases infected by pre-symptomatic or asymptomatic carriers in cluster investigations.(60–63) 412 
If asymptomatic infectious carriers are not characterized appropriately in models, epidemic 413 
infection rates would be underestimated, while the severity and the effectiveness of interventions 414 
would be overestimated, potentially leading to implementation of ineffective interventions. 415 
Serological studies will be critical for understanding the role of asymptomatic transmission. 416 
 417 
Early evidence suggests that travel restrictions result in only modest decreases in the 418 
importation of cases. However, combined with other social distancing measures and behavior 419 
changes, travel restrictions may be a useful addition. Modeling can be extremely valuable in 420 
providing counterfactuals aimed at disentangling the effects of different NPIs. Documentation of 421 
timing, type of NPI, and compliance rate will be needed to estimate the effectiveness of the 422 
different interventions.  423 
 424 
Reserved space. Do not place any text in this section. Include the mandatory author checklist or 
your manuscript will be returned. Use continuous line numbering in your manuscript.  
 
This paper is subject to additional limitations. To utilize the latest information, we 425 
included a number of pre-print reports that have not been formally peer-reviewed. Additionally, 426 
there is a heavy reliance on data from China, due to the period considered. Given the recent 427 
geographic spread of COVID-19, there may be a range of future estimates that will differ from 428 
those reported here. Finally, we have not performed a formal assessment of possible biases of the 429 
estimates examined in this paper, and therefore cannot exclude that some estimates reported are 430 
affected by unmeasured sources of biases. 431 
 432 
As the COVID-19 epidemic progresses, ongoing refinement and validation of key 433 
epidemiological parameters will help inform the global public health response. Defining optimal 434 
surveillance methods, laboratory testing, contact tracing parameters, quarantine measures, 435 
hospital acute care capacities, and many other operational factors, depends on estimates of the 436 
epidemiological parameters summarized in this paper. One of the largest knowledge gaps are 437 
those of asymptomatic or pre-symptomatic infectious potential and the occurrence of subclinical 438 
infections. In the absence of efficacious vaccines and therapeutics, developing an evidence-base 439 
for NPIs will remain a critical tool for effective local, national, and global outbreak control.  440 
Better data will enable mathematical and statistical modeling to more precisely predict how 441 
different NPIs can be combined to produce efficient epidemic control. 442 
 443 
Our summary provides estimates through the first 10 weeks of the COVID-19 epidemic 444 
that are needed for operational planning, scenario-building for contingency planning and 445 
forecasting to inform today’s preparedness and response efforts. Data from outbreaks in newly 446 
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affected countries and new data stemming from sero-prevalence and transmission studies will 447 
provide insights currently unavailable. Documenting and evaluating NPIs will help public health 448 
and government decision makers to implement the most effective epidemic control measures.  449 
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 670 
Tables 671 
Table 1. Key parameters and definitions 672 
Parameter Definition 
Basic Reproduction 
Number (R0) 
The average number of people infected by a single infected individual in a fully susceptible population 
Time-varying or effective 
reproduction number (R, 
Rt, RE) 
The average number of people infected by an infected individual in a population in the context of changing 
transmission patterns such as those resulting from interventions and acquired immunity 
Incubation Period The time between infection and symptom onset 
Serial Interval The average time between symptom onset of a primary case and symptom onset of linked secondary 
cases 
Generation Interval The average time between infection of a primary case and infection of linked secondary cases 
Doubling Time The average time period it takes for the daily case count to double 
Infectious Period The period of time in which an infected host, with or without symptoms, can transmit an infectious agent to 
susceptible individuals, directly or indirectly 
Case Fatality Ratio (CFR) The proportion of cases which result in death (with case defined in numerous ways) 
Infection Fatality Ratio 
(IFR) 
The proportion of all infections (including confirmed, symptomatic, asymptomatic, etc.) which result in 
death 
Mean Evolutionary rate  The average rate at which mutations accumulate per base pair in the genome over the course of a year 
 673 
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Table 2. Summary of Estimates of Mean Evolutionary Rate and Most Recent Common Ancestor 674 
(MRCA) 675 
Mean Evolutionary 
Rate (95% CI)* 
MRCA (95% CI) Number of 
Genomes in 
Analysis 
Clock Model** Growth Model Source 
- 29 Nov 2019 (8 Nov 2019 – 16 
Dec 2019) 
23 Strict Constant Rambaut, 
unpub. data, 
http://virologic
al.org/t/phylog
enetic-
analysis-of-23-
ncov-2019-
genomes-
2020-01-
23/335 
1.23x10-3 (0.56x10-
3- 1.98x10-3) 
21 Nov 2019 (23 Oct 2019 - 13 
Dec 2019) 
51 Strict Exponential Duchene et 
al., unpub. 
data, 
http://virologic
al.org/t/tempor
al-signal-and-
the-
evolutionary-
rate-of-2019-
n-cov-using-
47-genomes-
collected-by-
feb-01-
2020/379.  
1.29x10-3 
(0.535x10-4- 
2.15x10-3) 
14 Nov 2019 (28 Sept 2019- 13 
Dec 2019) 
51 UNCL*** Exponential Duchene et 
al., unpub. 
data, 
http://virologic
al.org/t/tempor
al-signal-and-
the-
evolutionary-
rate-of-2019-
n-cov-using-
47-genomes-
collected-by-
feb-01-
2020/379.  
0.9x10-3 (0.5x10-3- 
1.4x10-3) 
3 Dec 2019 (30 Oct 2019- 17 Dec 
2019) 
51 Strict Exponential Bedford, 
unpub. data, 
http://virologic
al.org/t/phylod
ynamic-
estimation-of-
incidence-and-
prevalence-of-
novel-
coronavirus-
ncov-
infections-
through-
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time/391.  
0.92x10-3 (0.33x10-
3- 1.46x10-3) 
29 Nov 2019 (28 Oct 2019 - 20 
Dec 2019) 
75 Strict Exponential Rambaut, 
unpub. data, 
http://virologic
al.org/t/phylod
ynamic-
analysis-176-
genomes-6-
mar-2020/356. 
Accessed 
March 4, 2020 
1.04x10-3 (0.71x10-
3- 1.4x10-3) 
3 Dec 2019 (16 Nov 2019 - 17 
Dec 2019) 
116 Strict Exponential Hill and 
Rambaut, 
unpub. data, 
http://virologic
al.org/t/phylod
ynamic-
analysis-of-
sars-cov-2-
update-2020-
03-06/420 
7.41x10-4 (4.91x10-
4- 1.02x10-3) 
27 Nov 2019 (7 Nov 2019- 11 Dec 
2019) 
128 Strict Birth Death Model Sciré et al., 
unpub. data, 
http://virologic
al.org/t/update
-2-
evolutionary-
epidemiologic
al-analysis-of-
128-
genomes/423 
* confidence interval 676 
**The Clock Model is a technique that uses the mutation rate to estimate the time of emergence. 677 
(47) 678 
***Uncorrelated 679 
  680 
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Table 3. Summary of the studies of non-pharmaceutical interventions (NPI) 681 
Non-pharmaceutical intervention Summary/Results Source 
Case detection (27% - 37%) cases detected* Bhatia et al., 
unpub. data, 
https://www.impe
rial.ac.uk/media/i
mperial-
college/medicine/
sph/ide/gida-
fellowships/Imper
ial-College-
COVID19-
international-
surveillance-21-
02-2020.pdf  
Case detection 38% (22%-64%) cases detected Niehus et al., 
unpub. data, 
https://www.medr
xiv.org/content/1
0.1101/2020.02.
13.20022707v2 
Case screening and detection (36%-65%) cases detected* Pinotti et al., 
unpub. data, 
https://www.medr
xiv.org/content/1
0.1101/2020.02.
24.20027326v1 
Case isolation and contact tracing Delay of onset symptoms to isolation has a high impact on the 
results, affecting the controllability of the outbreak. Results vary by 
scenario. 
50 
Travel screening 34% (20%-50%) travelers identified through both departure and 
arrival screening using symptoms or risk screening 
Gostic et al., 
unpub. data, 
https://www.medr
xiv.org/content/1
0.1101/2020.01.
28.20019224v2 
Travel screening 46.5% (35.9% - 57.7%) travelers not detected through thermal 
screening 
51 
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Travel screening Syndromic screening and traveler sensitization in combination could 
delay outbreaks in yet unaffected countries up to 83 days (75% 36 
days, 97.5% 8 days) 
Clifford et al., 
unpub. data, 
https://cmmid.git
hub.io/topics/covi
d19/screening-
outbreak-
delay.html 
Travel reduction (transport suspension) Delay of 2.91 days (95% CI: 2.54-3.29) for the arrival of the disease 
to other cities in China. 
52 
Travel reduction (travel quarantine)  130 cities in China had ≥ 50% chance of having a COVID-19 case 
imported from Wuhan in the 3 weeks preceding the quarantine 
15 
Travel restrictions Travel restriction imposed on Wuhan delay the epidemic for 3 days 18 
Travel reduction (airline suspensions) Travel restriction imposed on China will delay the disease in other 
countries, the biggest delay being in Africa (11 days) and South 
America (9 days) 
Adiga et al., 
unpub. data, 
https://www.medr
xiv.org/content/1
0.1101/2020.02.
20.20025882v2; 
Travel reduction Travel restriction will delay the epidemic for 2 days. 53 
Cancellation of mass gathering 37% fewer cases when the interventions started before the first 
case. 
52 
Combination of NPI 66%, 86%, and 95% fewer cases depending on the timing of the 
interventions 
Lai et al., upub. 
data, 
https://www.medr
xiv.org/content/1
0.1101/2020.03.
03.20029843v3.f
ull.pdf 
Combination of NPI  50% fewer cases if transmissibility reduced by 25% in all cities in 
China. Delay of epidemic peak for one month. 
11 
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Combination of NPI Drastic control measures implemented in China have substantially 
mitigated the spread of COVID-19 
34 
Combination of NPI 
Earlier intervention of social distancing could significantly limit the 
epidemic in mainland China. The number of infections could be 
reduced up to 98.9%, and the number of deaths could be reduced 
by up to 99.3% as of Feb 23, 2020 
  
Zhang et al., 
unpub. data, 
https://www.medr
xiv.org/content/1
0.1101/2020.03.
04.20031187v1 
Community behavior modification At least 42% of the people interviewed have modified daily behavior. 54 
*point estimates 682 
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Legends for Figures 684 
Figure 1. Basic reproduction number (R0) estimates by date of last reported cases 685 
analyzed and location. Points are mean or median estimates and error bars indicate 90% (12, 13, 686 
18) or 95% bounds (i.e. confidence or credible intervals). International-China estimates are those 687 
using international cases or exported cases from China to infer R0 in China or Hubei. Estimates 688 
for China refer to R0 estimates at the national or province level, except for those exclusive 689 
estimating R0 for Hubei (China-Hubei). 690 
Figure 2. Estimated incubation period based on search in peer-reviewed (top) and gray 691 
literature (bottom). Point are mean, triangles are median estimates (if applicable) and error bars 692 
indicate confidence (blue) or credible intervals (red). 693 
Figure 3. Estimated serial interval based on search in peer-reviewed literature (top) and 694 
gray literature (bottom). Point are mean estimates, triangles are median estimates (if applicable) 695 
and error bars indicate confidence (blue) or credible intervals (red). 696 
 697 
Figure 4. Estimated doubling time based on search in peer-reviewed literature (top) and 698 
gray literature (bottom). Point are mean estimates and error bars indicate confidence (blue) or 699 
credible intervals (red). 700 
 701 
Figure 5. Summary of CFR and IFR estimates. Point are mean or median estimates and 702 
error bars indicate confidence (dotted line) or credible intervals (full line). Red color refers to 703 
Peer-reviewed and blue to non-Peer-reviewed papers.  704 
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Supplementary Figures and Tables 705 
Supplementary Table 1- Search Terms 706 
 707 
Topic Search Terms  
Virus Evolution “nCoV”, “2019-nCoV”, “nCoV-2019”, “COVID”, “COVID-19”, “novel coronavirus”, “SARS-CoV-2” 
AND  
“evolution*” or “phylogenetics” 
Incubation period In PubMed, medRxiv, bioRxiv and arXiv: 
#1: “incubation period” 
#2: "coronavirus" OR "nCoV" OR "COVID" OR "COVID-19" OR "2019-nCoV" OR "nCoV-2019" OR "SARS-
CoV-2" 
#3: #1 AND #2 
  
In SSRN: 
#1: “incubation period” 
#2: "coronavirus" OR "nCoV" OR "COVID" OR "COVID-19" OR "2019-nCoV" OR "nCoV-2019" OR "SARS-
CoV-2" 
#3: #1 AND search within each of the term in #2 
  
In research square, Virological, and Wellcome Open Research: 
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#1: "coronavirus" OR "nCoV" OR "COVID" OR "COVID-19" OR "2019-nCoV" OR "nCoV-2019" OR "SARS-
CoV-2" 
Then read through all the papers 
Serial interval In PubMed: 
#1: "serial interval" OR "generation interval" OR "generation time" OR "serial distribution" OR "secondary 
infections" OR "secondary cases" 
#2: "coronavirus" OR "nCoV" OR "COVID" OR "COVID-19" OR "2019-nCoV" OR "nCoV-2019" OR "SARS-
CoV-2" 
#3: #1 AND #2 
  
In medRxiv, bioRxiv, and arXiv: 
#1: "serial interval" 
#2: "coronavirus" OR "nCoV" OR "COVID" OR "COVID-19" OR "2019-nCoV" OR "nCoV-2019" OR "SARS-
CoV-2" 
#3: #1 AND #2 
  
In SSRN: 
#1: “serial interval” 
#2: "coronavirus" OR "nCoV" OR "COVID" OR "COVID-19" OR "2019-nCoV" OR "nCoV-2019" OR "SARS-
CoV-2" 
#3: #1 AND search within each of the term in #2 
  
In research square, Virological, and Wellcome Open Research: 
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#1: "coronavirus" OR "nCoV" OR "COVID" OR "COVID-19" OR "2019-nCoV" OR "nCoV-2019" OR "SARS-
CoV-2" 
Then read through all the papers 
Generation interval In PubMed and arXiv: 
#1: "generation interval" 
#2: "coronavirus" OR "nCoV" OR "COVID" OR "COVID-19" OR "2019-nCoV" OR "nCoV-2019" OR "SARS-
CoV-2" 
#3: #1 AND #2 
 
In medRxiv and bioRxiv: 
“generation interval” for full text or abstract or title (match whole all) 
 
In SSRN: 
#1: “generation interval” 
#2: "coronavirus" OR "nCoV" OR "COVID" OR "COVID-19" OR "2019-nCoV" OR "nCoV-2019" OR "SARS-
CoV-2" 
#3: #1 AND search within each of the term in #2 
 
In research square, Virological, and Wellcome Open Research: 
#1: "coronavirus" OR "nCoV" OR "COVID" OR "COVID-19" OR "2019-nCoV" OR "nCoV-2019" OR "SARS-
CoV-2" 
Then read through all the papers 
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Doubling time In PubMed, medRxiv, bioRxiv and arXiv: 
#1: “doubling time” OR “growth rate” 
#2: "coronavirus" OR "nCoV" OR "COVID" OR "COVID-19" OR "2019-nCoV" OR "nCoV-2019" OR "SARS-
CoV-2" 
#3: #1 AND #2 
  
In SSRN: 
#1: “doubling time” OR “growth rate” 
#2: "coronavirus" OR "nCoV" OR "COVID" OR "COVID-19" OR "2019-nCoV" OR "nCoV-2019" OR "SARS-
CoV-2" 
#3: #1 AND search within each of the term in #2 
  
In research square, Virological, and Wellcome Open Research: 
#1: "coronavirus" OR "nCoV" OR "COVID" OR "COVID-19" OR "2019-nCoV" OR "nCoV-2019" OR "SARS-
CoV-2" 
Then read through all the papers 
CFR In PubMed:  
("coronavirus"[MeSH Terms] OR "coronavirus"[All Fields] OR "2019-ncov"[All Fields] OR "COVID-19"[All Fields] 
OR "COVID"[All Fields] OR "SARS-COV-2"[All Fields] OR "ncov"[All Fields] OR "ncov-2019"[All Fields]) AND 
"2019/12/31 00.00"[MHDA] : "2020/03/06 23.59"[MHDA] AND ("fatality"[All Fields] OR "Case Fatality"[All Fields] 
OR "Infection Fatality"[All Fields]) 
 
In biorXiv & medrXiv: 
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for title "coronavirus fatality" (match all words) and abstract or title "coronavirus fatality" (match all words) and 
posted between "01 Jan, 2020 and 07 Mar, 2020" 
 
In arXiv: 
Query: order: -announced_date_first; size: 50; date_range: from 2020-01-01 to 2020-03-07; include_cross_list: 
True; terms: AND abstract=coronavirus; AND abstract=fatality 
 
In ResearchSquare:  
SARS-CoV-2 Preprints 
 
In Wellcome Research:  
Query: “coronavirus” 
 
In WHO Global Research Database:  
Query: “sever*” 
 
Cited by WHO: 
Imperial College London, IDO 
 
Non-Pharmaceutical 
Interventions 
In all databases:  
"coronavirus" OR "nCoV" OR "COVID" OR "COVID-19" OR "2019-nCoV" OR "nCoV- 2019" OR "SARS-CoV-2" 
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Supplementary Table 2.  Summary of the published study included in the review of incubation 709 
period, serial interval, doubling time and generation interval. 710 
 711 
Study Study setting Incubation period 
 (days) 
Serial interval  
(days) 
Doubling time 
 (days) 
Generation interval  
(days) 
Backer 2020 
(28) 
88 confirmed 
cases detected 
outside of 
Wuhan from 20 
Jan 2020 to 28 
Jan 2020 
Mean: 6.4, 
Median: NA, 
SD: 2.3, 
95% CrI: 5.6 to 7.7 based 
on Weibull distribution 
NA NA NA 
Chinazzi 2020 
[18] 
Modeling study NA NA 4.2 (90% CI: 3.8 to 4.7) 
based on reporting 
dates 
NA 
Du 2020a [15] Modeling study NA NA 7.31 (95% CrI: 6.26 to 
9.66) based on onset 
dates 
  
NA 
Ganyani 2020 
(34) 
Modeling study NA Mean: 5.21, 
Median: NA, 
SD: 4.32, 
95% CrI: -3.35 to 
13.94 in Singapore 
  
NA Mean: 5.20, 
Median: NA, 
SD: 1.72, 
95% CrI: 3.78 to 6.78  
in Singapore 
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Ganyani 2020 
(34) 
Modeling study NA Mean: 3.95, 
Median: NA, 
SD: 4.24, 
95% CrI: -4.47 to 
12.51 in Tianjin, China 
NA Mean: 3.95, 
Median: NA, 
SD: 1.51, 
95% CrI: 3.01 to 4.91  
in Tianjin, China 
Jung 2020 
(19) 
Modeling study NA NA 2.39 (95% CI: 1.93 to 
3.15) from 20 exported 
cases reported by 24 
Jan 2020, calculated by 
growth rate of 0.29 
(95% CI: 0.22 to 0.36) 
based on reporting 
dates 
 
 
Leung 2020 
(30) 
175 confirmed 
patients in China 
from 20 Jan 
2020 to 12 Feb 
2020 
 
Mean: 1.8, 
Median: NA, 
SD: NA, 
95% CI: 1.0 to 2.7 
based on travelers to 
Hubei fitting to Weibull 
distribution; 
NA NA  
Leung 2020 
(30) 
175 confirmed 
patients in China 
from 20 Jan 
2020 to 12 Feb 
2020 
 
Mean: 7.2, 
Median: NA, 
SD: NA, 
95% CI: 6.1 to 8.4 
based on non-travelers 
fitting to Weibull 
distribution  
NA NA  
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Li 2020 (9) 425 confirmed 
cases in Wuhan 
as of 22 Jan 
2020 
Mean: 5.2, 
Median: NA, 
SD: NA, 
95% CI: 4.1 to 7.0 
based on log-normal 
distribution 
  
Mean: 7.5, 
Median: NA, 
SD: 3.4, 
95% CI: 5.3 to 19.0 
based on gamma 
distribution 
  
7.4 (95% CI: 4.2 to 
14.0) based on onset 
dates 
 
Linton 2020 
(29) 
158 confirmed 
cases in and 
outside of 
Wuhan as of 31 
Jan 2020 (52 
cases when 
excluding 
Wuhan 
residents) 
Mean: 5.6, 
Median: NA, 
SD: NA, 
95% CrI: 5.0 to 6.3 
based on 158 cases; 
  
NA NA  
Linton 2020 
(29) 
158 confirmed 
cases in and 
outside of 
Wuhan as of 31 
Jan 2020 (52 
cases when 
excluding 
Wuhan 
residents) 
Mean: 5.0, 
Median: NA, 
SD: NA, 
95% CrI: 4.2 to 6.0 
based on 52 cases 
  
NA NA  
Nishiura 2020 
(33) 
28 infector-
infectee pairs 
from published 
research articles 
as of 12 Feb 
2020 
NA Mean: 4.7, 
Median: 4.0, 
SD: 2.9, 
95% CrI: 3.7 to 6.0 
based all 28 pairs 
fitting to log-normal 
distribution  
NA  
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Nishiura 2020 
(33) 
18 pairs with 
highest certainty 
from published 
research articles 
as of 12 Feb 
2020 
NA Mean: 4.8, 
Median: 4.6, 
SD: 2.3, 
95% CrI: 3.8 to 6.1 
based on 18 certain 
pairs fitting to Weibull 
distribution 
  
NA  
Sanche 2020 
(35) 
Modeling study NA NA 2.4 (95% CI: 1.9, 3.3) 
based on onset dates 
  
 
Wu 2020 (11) Modeling study NA NA 6.4 (95% CrI: 5.8 to 
7.1) based on onset 
dates 
 
Zhang 2020 
(31) 
8579 confirmed 
cases reported 
outside Hubei in 
China as of 17 
Feb 2020 (only 
49 cases with no 
travel history 
to/from 
Wuhan/Hubei) 
Mean: 5.2, 
Median: NA, 
SD: NA, 
95% CI: 1.8 to 12.4 
based on log-normal 
distribution 
Mean: 5.1, 
Median: NA, 
SD: NA, 
95% CI: 1.3 to 11.6 
based on gamma 
distribution 
  
NA  
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Supplementary Table 3. Summary of the study included in the review of incubation period, serial 713 
interval, doubling time based on search in gray literature 714 
 715 
Study Study setting Incubation period 
(days) 
Serial interval (days) Doubling time (days) 
Bedford, 
unpub. data, 
http://virologic
al.org/t/phylod
ynamic-
estimation-of-
incidence-and-
prevalence-of-
novel-
coronavirus-
ncov-
infections-
through-
time/39 
53 publicly available nCoV 
genomes collected 
between 24 Dec, 2019 
and 4 Feb, 2020 
NA NA 7.2 (95% CI: 5.0 to 12.9) 
based on sample 
collection dates 
Lu et al., 
unpub. data, 
https://www.m
edrxiv.org/cont
ent/10.1101/2
020.02.19.200
25031v1  
265 confirmed cases in 
Shanghai before 7 Feb 
2020 (only 27 had credible 
contact information) 
Mean: 6.4, 
Median: NA, 
SD: NA, 
95% CI: 5.3 to 7.6 
based on Weibull 
distribution 
  
NA NA 
Pinotti et al., 
unpub. data, 
https://www.m
edrxiv.org/cont
ent/10.1101/2
020.02.24.200
27326v1 
Modeling study 
  
NA NA 2.67 (95% CI: 2.24 to 
3.30) importations from 
Hubei, calculated by 
growth rate of 0.26 (95% 
CI: 0.21 to 0.31) based 
on reporting dates 
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Rambaut, 
unpub. data, 
http://virologic
al.org/t/phylod
ynamic-
analysis-176-
genomes-6-
mar-2020/356 
75 genomes in 12 Feb 
2020, 86 genomes in 24 
Feb 2020 
NA NA 6.2 (95% CI: 4.1 to 12.3) 
75 genomes based on 
sample collection dates 
  
Rambaut, 
unpub. data, 
http://virologic
al.org/t/phylod
ynamic-
analysis-176-
genomes-6-
mar-2020/356 
75 genomes in 12 Feb 
2020, 86 genomes in 24 
Feb 2020 
NA NA 7.2 (95% CI: 4.7 to 16.3) 
86 genomes based on 
sample collection dates 
  
Tindale et al., 
unpub. data, 
https://www.m
edrxiv.org/cont
ent/10.1101/2
020.03.03.200
29983v1 
93 confirmed cases in 
Singapore from 19 Jan 
2020 to 26 Feb 2020 
  
Mean: 7.11, 
Median: 6.55, 
SD: NA, 
95% CI: 6.13 to 8.25 
based on Weibull 
distribution 
  
Mean: 4.56, 
Median: NA, 
SD: 0.95, 
95% CI: 2.69 to 6.42 
based on expectation-
maximization approach 
 
NA 
Tindale et al., 
unpub. data, 
https://www.m
edrxiv.org/cont
ent/10.1101/2
020.03.03.200
29983v1 
125 confirmed cases in 
Tianjin from 21 Jan 2020 
to 22  Feb 2020 
  
Mean: 9.02, 
Median: 8.62, 
SD: NA, 
95% CI: 7.92 to 10.2 
based on Weibull 
distribution 
  
Mean: 4.22, 
Median: NA, 
SD: 0.4, 
95% CI: 3.43 to 5.01 
based on expectation-
maximization approach 
  
NA 
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Zhang et al., 
unpub. data, 
https://www.m
edrxiv.org/cont
ent/10.1101/2
020.03.04.200
31187v1 
8579 confirmed cases 
reported outside Hubei in 
China as of 17 Feb 2020 
(only 49 cases with no 
travel history to/from 
Wuhan/Hubei) 
  
Mean: 5.2, 
Median: NA, 
SD: NA, 
95% CI: 1.8 to 12.4 
based on log-normal 
distribution 
Mean: 5.1, 
Median: NA, 
SD: NA, 
95% CI: 1.3 to 11.6 
based on gamma 
distribution 
  
NA 
Volz et al., 
unpub. data, 
https://www.im
perial.ac.uk/m
edia/imperial-
college/medici
ne/sph/ide/gid
a-
fellowships/Im
perial-College-
--COVID-19---
genetic-
analysis-
FINAL.pdf 
Phylogenetic analysis of 
53 SARS-CoV-2 whole 
genome sequences 
NA NA 7.1 (95% CI: 3.0 to 20.5) 
based on sample 
collection dates 
 
Zhao et al., 
unpub. data, 
https://www.m
edrxiv.org/cont
ent/10.1101/2
020.02.21.200
26559v1 
 
 
 
 
 
 
 
 
 
21 infector-infectee pairs 
in Hong Kong from 16 Jan 
2020 to 15 Feb 2020 
 
NA 
 
Mean: 4.4, 
Median: NA, 
SD: 3.0, 
95% CI: 2.9 to 6.7, 
based on gamma 
distribution 
  
 
NA 
Zhao et al., 
unpub. data, 
https://www.m
edrxiv.org/cont
ent/10.1101/2
020.02.06.200
20941v1 
 
Modeling Study NA NA 2.9 (95% CrI: 2 to 4.1) 
based on onset dates 
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Supplementary Table 4. Frequency of different case severities 718 
 719 
Classification Definition Proportion * 
Mild/Moderate non-pneumonia and pneumonia cases 80.9% 
Severe dyspnea, respiratory frequency ≥ 30/minute, blood oxygen saturation ≤93%, 
PaO2/FiO2 ratio <300, and/or lung infiltrates >50% within 24–48 hours 
13.8% 
Critical respiratory failure, septic shock, and/or multiple organ dysfunction/failure 6.1% 
 720 
* Proportion out of 55,924 cases until Feb 20th   721 
 722 
 723 
  724 
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Supplementary Table 5- Summary of CFR and IFR Estimate Sources 725 
Author Place Metr
ic 
Estimate Uncertai
nty type 
Peer-
revie
wed 
Source 
Russell et 
al 
China IFR 0.6 (0.2-
1.3) 
95% CI Yes https://www.ncbi.nlm.nih.gov/pubmed/32234121 
Hauser et 
al 
China Hubei IFR 3.3 (2-4.7) 95% CrI No https://www.medrxiv.org/content/10.1101/2020.03.0
4.20031104v2.full.pdf 
Famulare China 
Wuhan 
IFR 0.9 (0.4-
2.9) 
95% CI No https://institutefordiseasemodeling.github.io/nCoV-
public/analyses/first_adjusted_mortality_estimates_
and_risk_assessment/2019-nCoV-
preliminary_age_and_time_adjusted_mortality_rate
s_and_pandemic_risk_assessment.html 
Mizumoto 
et al 
China 
Wuhan 
IFR 0.2 (0.2-
0.3) 
95% CrI No https://www.medrxiv.org/content/10.1101/2020.02.1
2.20022434v1 
Russell et 
al 
Diamond 
Princess 
IFR 1.3 (0.4-
3.6) 
95% CI Yes https://www.ncbi.nlm.nih.gov/pubmed/32234121 
Hauser et 
al 
Italy 
Northern 
IFR 3 (2.6-3.4) 95% CrI No https://www.medrxiv.org/content/10.1101/2020.03.0
4.20031104v1.full.pdf 
Nishiura et 
al + 
mainland 
China 
IFR NA (0.3-
0.6) 
95% CI Yes https://www.mdpi.com/2077-0383/9/2/419 
Verity et al mainland 
China 
IFR 0.7 (0.4-
1.3) 
95% CrI Yes https://www.thelancet.com/journals/laninf/article/PII
S1473-3099(20)30243-7/fulltext 
Russell et 
al 
China CFR 1.2 (0.3-
2.7) 
95% CI Yes https://www.ncbi.nlm.nih.gov/pubmed/32234121 
Deng et al China Hubei CFR 5.4 (5.3-
5.6) 
95% CI No https://www.medrxiv.org/content/10.1101/2020.03.0
4.20031005v1 
Mizumoto 
et al 
China Hubei 
not Wuhan 
CFR 0.9 (0.6-
1.3) 
95% CrI No https://www.medrxiv.org/content/10.1101/2020.02.1
9.20025163v1 
Deng et al China not 
Hubei 
CFR 0.9 (0.8-
1.1) 
95% CI No https://www.medrxiv.org/content/10.1101/2020.03.0
4.20031005v1 
Deng et al China not 
Wuhan 
CFR 3.5 (3.4-
3.8) 
95% CI No https://www.medrxiv.org/content/10.1101/2020.03.0
4.20031005v1 
Deng et al China 
Wuhan 
CFR 6.2 (6.1-
6.4) 
95% CI No https://www.medrxiv.org/content/10.1101/2020.03.0
4.20031005v1 
Mizumoto 
et al 
China 
Wuhan 
CFR 18.9 (17.1-
20.8) 
95% CrI No https://www.medrxiv.org/content/10.1101/2020.02.1
9.20025163v1 
Russell et 
al 
Diamond 
Princess 
CFR 2.6 (0.9-
6.7) 
95% CI Yes https://www.ncbi.nlm.nih.gov/pubmed/32234121 
Deng et al mainland 
China 
CFR 4.5 (4.5-
4.7) 
95% CI No https://www.medrxiv.org/content/10.1101/2020.03.0
4.20031005v1 
Wang et al China Hubei sCF
R 
7.2 (6.6-8) 95% CI No https://www.medrxiv.org/content/10.1101/2020.02.1
7.20023630v4 
Wang et al China not 
Hubei 
sCF
R 
1 (0.9-1.2) 95% CI No https://www.medrxiv.org/content/10.1101/2020.02.1
7.20023630v4 
Verity et al mainland 
China 
sCF
R 
1.4 (1.2-
1.5) 
95% CrI Yes https://www.thelancet.com/journals/laninf/article/PII
S1473-3099(20)30243-7/fulltext 
Famulare China 
Wuhan 
cCF
R 
33 (29-37) 95% CI No https://institutefordiseasemodeling.github.io/nCoV-
public/analyses/first_adjusted_mortality_estimates_
and_risk_assessment/2019-nCoV-
preliminary_age_and_time_adjusted_mortality_rate
s_and_pandemic_risk_assessment.html 
Jung et al * mainland 
China 
cCF
R 
5.3 (3.5-
7.5) 
95% CI Yes https://www.ncbi.nlm.nih.gov/pubmed/32075152 
Jung et al 
** 
mainland 
China 
cCF
R 
8.4 (5.3-
12.3) 
95% CI Yes https://www.ncbi.nlm.nih.gov/pubmed/32075152 
Verity et al outside 
mainland 
China (non-
parametric) 
cCF
R 
4.1 (2.1-
7.8) 
95% CrI Yes https://www.thelancet.com/journals/laninf/article/PII
S1473-3099(20)30243-7/fulltext 
Verity et al outside 
mainland 
China 
(parametric) 
cCF
R 
2.7 (1.4-
4.7) 
95% CrI Yes https://www.thelancet.com/journals/laninf/article/PII
S1473-3099(20)30243-7/fulltext 
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Wu et al China 
Wuhan 
HFR 14 (3.9-32) 95% CI Yes https://www.eurosurveillance.org/content/10.2807/1
560-7917.ES.2020.25.3.2000044 
Deng et al China Hubei ciCF
R 
25.7 (25.4-
26.5) 
95% CI No https://www.medrxiv.org/content/10.1101/2020.03.0
4.20031005v1 
Deng et al China not 
Hubei 
ciCF
R 
8 (7.5-9.6) 95% CI No https://www.medrxiv.org/content/10.1101/2020.03.0
4.20031005v1 
Deng et al China not 
Wuhan 
ciCF
R 
28.8 (28-
31) 
95% CI No https://www.medrxiv.org/content/10.1101/2020.03.0
4.20031005v1 
Deng et al China 
Wuhan 
ciCF
R 
26.9 (26.6-
27.9) 
95% CI No https://www.medrxiv.org/content/10.1101/2020.03.0
4.20031005v1 
Deng et al mainland 
China 
ciCF
R 
24.2 (23.9-
25) 
95% CI No https://www.medrxiv.org/content/10.1101/2020.03.0
4.20031005v1 
 726 
+.  Range based on ~10% ascertainment  727 
*. Fitted to epidemic growth alone 728 
**. Fitted to epidemic growth along with other parameters 729 
 730 
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Supplementary Table 6- Types of NPIs that could be implemented at the individual and 732 
community level 733 
  Non-pharmaceutical intervention 
Interventions for individuals Voluntary home isolation. Separation of ill people with contagious diseases from non-
infected persons  
Voluntary home quarantine. Restriction of people who are presumed to have been exposed 
to a contagious disease but are not ill, either because they did not become infected or because 
they are still in the incubation period. 
Community level  School closure (closure of day care facilities, schools and higher education) 
Workplace closure (closure of non-essential services) 
Cancel or postpone large public gatherings  
 734 
 735 
  736 
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Supplementary Table 7- Definition of NPIs search key words 737 
Topic Definition 
‘case detection’, ‘case detected’ Detection of cases imported from an affected area 
‘case isolation and contact tracing’ Isolation of an identified positive case. 
‘travel screening’ Screening of passengers at port of exit/entry 
‘travel reduction’, ‘reduced travel’, ‘airline suspension’ Mobility reduction of individuals, intra- or inter- city/country. 
‘school closure’ Closing schools to prevent further transmission 
‘Cancellation of events and mass gatherings’, ‘Lockdown’ Cancellation of events and mass gatherings in order to prevent 
further transmission. 
‘Community response’ People’s psychological and behavioral responses during an 
outbreak 
In Table 7 we present a short definition of the search keywords related to the non-pharmaceutical 738 
intervention we are interested in. As there are not specific terms to describe these interventions, 739 
or there are different terms to describe the same kind of intervention, we considered them to be 740 
equivalent. 741 
 742 
